First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients
DARTMOUTH, Nova Scotia, Jan. 17, 2019 (GLOBE NEWSWIRE) — IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that the first patient has been treated in the Phase 1 trial evaluating neoepitopes formulated in the Company’s proprietary DPX delivery platform in patients with ovarian cancer. The study is part of the Company’s DPX-NEO program, which is an ongoing collaboration between UConn Health and IMV to develop neoepitope-based anti-cancer therapies.
“Expanding our DPX-based clinical immunotherapy program beyond DPX-Survivac is an important milestone for IMV, and we are pleased to be able to do so with this type of cutting-edge program in which the novel mechanism of action underscoring all DPX-based candidates plays a critical role,” said Frederic Ors, Chief Executive Officer at IMV. “We believe that the potential of neoepitope-based therapies could be a significant advance in the way physicians treat patients with ovarian cancer who today face a high unmet medical need. We look forward to working with UConn Healthto advance this program as IMV is committed to developing an immunotherapy option for women affected by this disease.”
Investigators will assess the safety and efficacy of using patient-specific neoepitopes discovered at UConn Health and formulated in IMV’s proprietary DPX-based delivery technology in women with ovarian cancer. Investigators plan to enroll up to 15 patients in the Phase 1 study. UConn Health is funding the trial with IMV providing materials and counsel.
Epitopes are the part of the biological molecule that is the target of an immune response. Neoepitopes are the mutated proteins produced by a patient’s own tumors. Neoepitope immunotherapies target these patient-specific proteins and have been referred to as ‘the next immunotherapy frontier.’ (1)“The first immunization of the first ovarian cancer patient with our personalized, patient-specific neoepitopes developed at the University of Connecticut using our proprietary technology, formulated in IMV’s excellent immunomodulatory DPX delivery platform, is a major milestone for us,” said Study Investigator Pramod K Srivastava, PhD, MD, Director of the Neag Comprehensive Cancer Center at the University of Connecticut School of Medicine. About the DPX-NEO Program
The DPX-NEO program is an ongoing collaboration evaluating the anti-cancer activity of proprietary patient-specific epitopes developed at UConn Health and formulated in IMV’s DPX-based novel immunotherapeutic delivery technology. IMV had previously announced the results from preclinical research in which researchers at UConn found that neoepitopes formulated in DPX-based formulations demonstrated superior immunogenic activity over comparators in mouse tumor models. In addition, IMV also previously announced a breakthrough in formulating multiple peptides in DPX formulations. The Company has patented the technology, which allows for both a larger number and a broader potential range of peptides into a single formulation as compared to standard formulation technologies.
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Incyte and Merck. Connect at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Corporation, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties and those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of clinical trials, the receipt of all regulatory approvals and other risks detailed from time to time in our ongoing quarterly filings and annual information form Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV’s continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar.Contacts for IMV: MEDIA Andrea Cohen, Sam Brown Inc. T: (917) 209-7163 E: AndreaCohen@sambrown.com INVESTOR RELATIONS Marc Jasmin, IMV Senior Director, Investor Relations T: (902) 492-1819 E: firstname.lastname@example.org Patti Bank, Managing Director, Westwicke Partners O: (415) 513-1284 T: (415) 515-4572 E: email@example.com REFERENCES 1 Neoepitope Vaccines, Next Immunotherapy Frontier Cancer Discovery Published Online First December 28, 2015; doi:10.1158/2159-8290.CD-NB2015-179 Source: IMV Inc.
DARTMOUTH, Nova Scotia, Sept. 04, 2018 (GLOBE NEWSWIRE) — IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, celebrated its grand opening today of its new facilities in Dartmouth, Nova Scotia. Frederic Ors, IMV’s Chief Executive Officer, and Andrew Sheldon, IMV’s Chairman of the Board, opened today’s event with remarks about the company’s milestones and successes. Other speakers included federal MP Darren Fisher, the Honourable Randy Delorey, Minister of Health and Wellness, and Dartmouth Centre Councillor Sam Austin. Emilie Chiasson, the Atlantic Regional Director of Ovarian Cancer Canada, served as the event’s Master of Ceremonies.
NEWS RELEASE HALIFAX, April 21, 2016 — On Tuesday the Nova Scotia government tabled its 2016-17 Budget with a surplus of $17.1 million and a commitment to work collaboratively with industries with big potential in the province. As part of the Budget address, the province called for a collaborative approach model to boost the economy. “This government understands that we cannot solve our economic problems alone. We need to work together to create a stronger economy, a stronger Nova Scotia,..” stated the- Hon. Randy Delorey, Minister of Finance as part of Budget 2016-2017 The life sciences industry in Nova Scotia has indicated it is ready to work with government and is poised as a growth facilitator for the province’s future economic and social prosperity. Generating nearly $300 million in revenues for the province and exporting up to 90% of products, the sector offers a strong and sustainable economic strategy. “With further support from the province for the life sciences community to develop their ideas, commercialize their technologies and build links within the region and internationally we will continue to be a wealth generator for the province,” said Scott Moffitt, Managing Director of BioNova, the life science industry association. The industry has also been fostering valuable collaborative relationships with national associations such as Innovative Medicines Canada to accelerate the development of local pharmaceutical companies, as evidenced by the recent signing of a memorandum of understanding to enhance Nova Scotia’s medical technology portfolio. In recent years, the local life sciences industry has also seen a significant increase in innovation and potential coming from Nova Scotia companies. Immunovaccine Inc. is a good example of this, with a greater than $60 million market cap and a new CEO focused on industry collaborations to continue down the path of growth. The $540 million acquisition of Nova Scotia-based Ocean Nutrition Canada by Royal DSM, a global life science and material sciences company, is another example of growth in the sector. “It’s easy to imagine what more growth in this sector could lead to for Nova Scotians. We look forward to building strong links with the Government of Nova Scotia to further innovation in Nova Scotia’s life sciences sector,” said Russell Williams, President of Innovative Medicines Canada. ABOUT BIONOVA BioNova is Nova Scotia’s life sciences industry association and sector development organization. BioNova leads and supports its members as we build a successful, self-sustaining life sciences industry in Nova Scotia. By promoting the industry and its successes, building relationships both inside and outside the province and creating networking and educational opportunities BioNova aims to accelerate the commercialization success of Nova Scotia’s life sciences businesses and organizations. ABOUT INNOVATIVE MEDICINES CANADA Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system. – 30 – For further information: Shana McRae Marketing & Communications Officer, BioNova Telephone: 902-421-5705 ext. 2 E-mail: firstname.lastname@example.org Sarah Douglas Media Relations, Innovative Medicines Canada Telephone: 613-883-7250 E-mail: email@example.com]]>